Patents by Inventor David S. Lukeman

David S. Lukeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and composition for treating thrombosis
    Patent number: 6395873
    Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic. moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 28, 2002
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig, Juerg F. Tschopp
  • Method and composition for treating thrombosis
    Patent number: 6100236
    Abstract: The invention provides RGD containing peptides which are cyclized and contain hydrophobic moieties adjacent the carboxy terminus of the RGD sequence. Such peptides have an high affinity for the receptor IIb/IIIa and low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 8, 2000
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig
  • Method and composition for treating thrombosis
    Patent number: 6017877
    Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: January 25, 2000
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig, Juerg F. Tschopp
  • Method and composition for treating thrombosis
    Patent number: 6013625
    Abstract: The invention provides RGD containing peptides which are cyclized and contain hydrophobic moieties adjacent the carboxy terminus of the RGD sequence. Such peptides have an high affinity for the receptor IIb/IIIa and low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: January 11, 2000
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig
  • Method and composition for treating vascular graft occlusion
    Patent number: 5648330
    Abstract: The invention provides RGD containing peptides which are cyclized and contain hydrophobic moieties adjacent the carboxy terminus of the RGD sequence. Such peptides have an high affinity for the receptor IIb/IIIa and low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 15, 1997
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig
  • Method and composition for treating thrombosis
    Patent number: 5612311
    Abstract: The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: March 18, 1997
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Michael D. Pierschbacher, David S. Lukeman, Soan Cheng, William S. Craig, Juerg F. Tschopp